CD10 AND CD34 EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN MOROCCO: Clinical Relevance and Outcome

REFERENCES

• Vidriales M B, San-Miguel J F, Orfao A, et al. Minimal residual disease monitoring by flow cytometry. Best Practice & Res Clin Haematol. 2003; 16: 599–612
   PubMed Web of Science ®Google Scholar
• Letarte M, Vera S, Tran R, et al. Common acute lymphoblastic leukemia antigen is identical to neutral endopeptidase. J Exp Med 1988; 168: 1247–1253
   PubMed Web of Science ®Google Scholar
• Cossman J, Neckers L M, Leonard W J, et al. Polymorphonuclear neutriphils express the common acute lymphoblastic leukemia antigen. J Exp Med 1983; 157: 1064–1069
   Google Scholar
• Ludwig W D, Haferlach T, Schoch C. Classification of Acute Leukemias. Treatment of Acute Leukemias, C H Pui. Humana Press, Totowa, NJ 2003; 3–41, New Directions for Clinical Research
   Google Scholar
• Lanza F, Healy L, Sutherland D R. Strucural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents 2001; 15: 1–13
   PubMed Web of Science ®Google Scholar
• Simmons P J, Torok-Storb B. CD34 expression by stromal precursors in normal human adult bone marrow. Blood 1991; 78: 2848–2853
   PubMed Web of Science ®Google Scholar
• Pui C H, Rivera G K, Hancock M L, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic. Leukemia 1993; 7: 35–40
   PubMed Web of Science ®Google Scholar
• Pui C H, Hancock M L, Head D R, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 1993; 82: 889–894
   PubMed Web of Science ®Google Scholar
• Rivera-Luna R, Cardenas-Cardos R, Leal-Leal C, et al. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. Arch Med Res 1997; 28: 233–239
   PubMedGoogle Scholar
• Pui C H, Willliams D L, Raimondi S C, et al. Unfavorable presenting clinical and laboratory features are associated with CALLA-negative non-T, non-B lymphoblastic leukemia in children. Leukemia Res 1986; 10: 1287–1292
   PubMed Web of Science ®Google Scholar
• Vannier J P, Bene M C, Faure G C, et al. Investigation of the CD10 (CALLA) negative acute lymphoblastic leukaemia: further description of a group with a poor prognosis. Br J Haematol 1989; 72: 156–160
   PubMed Web of Science ®Google Scholar
• Pui C H, Crist W M. High risk lymphoblastic leukemia in children: prognostic factors and management. Blood Rev 1987; 1: 25–33
   PubMedGoogle Scholar
• Basso G, Rondelli R, Putti M C, . Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP cooperative study. Recent Results in Cancer Research, W D Ludwig, E Thiel, et al. Springer, Berlin 1993; 297–307
   Google Scholar
• Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL. Haematologica 1998; 83: 967–973
   Google Scholar
• Borowitz M J, Shuster J, Curt I, et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a pediatric oncology group study. J Clin Oncol 1990; 8: 1389–1398
   PubMed Web of Science ®Google Scholar
• Vanhaeke D R, Bene M C, Garand R, et al. Expression and long-term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia. Leukemia Lymphoma. 1995; 20: 137–142
   PubMed Web of Science ®Google Scholar
• Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16: 1233–1258
   PubMed Web of Science ®Google Scholar
• WHO. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues, , et al. IARC Press, LyonFrance 2001
   Google Scholar
• Schabath R, Ratei R, Ludwig W-D. The prognostic significance of antigen expression in leukemia. Best Practice Res Clin Haematol 2003; 16: 613–628
   PubMed Web of Science ®Google Scholar
• Baruchel A, Leverger G, Schaison G. Use of immunophenotype as part of the prognostic stratification for childhood ALL in the FRALLE 93 protocol. Leukemia Lymphoma. 1994; 13(Suppl 1)91–93
   Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. the FAB Cooperative Group. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Hematol 1981; 47: 553–561
   PubMed Web of Science ®Google Scholar
• Owens M A, Vall H G, Hurley A A, et al. Validation and quality control of immunophenotyping in clinical flow cytometry. J Immunol Methods 2000; 243: 33–50
   Google Scholar
• Béné M C, Castoldi G, Knapp W, et al. Proposal for immunological classification of acute leukemias. European Group for the Immunological Characterisation of Leukaemias (EGIL). Leukemia 1995; 9: 1783–1786
   PubMed Web of Science ®Google Scholar
• Dakka N, Bellaoui H, Khattab M, et al. Immunological profile and outcome of childhood acute lymphoblastic leukemia (ALL) in Morocco. J Pediatr Hematol Oncol 2007; 29: 574–580
   Google Scholar
• Schaison G, Leverger G, Bancillon A, et al. Intermediate risk childhood acute lymphoblastic leukemias: amsacrine+cytosine arabinoside versus intermediate dose methotrexate for consolidation, and 6-mercaptopurine+methotraxate+vincristine versus monthly pulses for maintenance. Haematol Blood Transfus. 1987; 30: 461–465
   Google Scholar
• Schaison G, Auclerc M F, Baruchel A, et al. Prognosis of acute lymphoblastic leuemiain children: results of the French protocol FRALLE 93. Bull Acad Natl Med 2001; 185: 149–66
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Schrappe M, Stanulla M. Treatment of childhood acute lymphoblastic leukaemia. Treatment of Acute Leukemias, C H Pui. Humana Press, Totowa, NJ 2003; 87–104, New Directions for Clinical Research
   Google Scholar
• Pui C H, Behm F G, Crist W M. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343–362
   PubMed Web of Science ®Google Scholar
• Hann I M, Richards S M, Eden O B, et al. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia 1998; 12: 1249–1255
   PubMed Web of Science ®Google Scholar
• Stahnke K, Eckhoff S, Mohr A, et al. Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia 2003; 17: 2130–2139
   PubMed Web of Science ®Google Scholar
• Thomas X, Archimbaud E, Charrin C, et al. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia. Leukemia. 1995; 9: 249–253
   PubMed Web of Science ®Google Scholar
• Van Wering E R, Van Der Linden-Shrever B E, Szczepanski T, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol. 2000; 110: 139–146
   PubMed Web of Science ®Google Scholar
• Basso G, Lanza F, Orfao A, et al. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeos Agents 2001; 15: 68–78
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18–24
   PubMed Web of Science ®Google Scholar
• Pui C H, Campana D, Evans W E. Childhood acute lymphobastic leukaemia: current status and future perspectives. Lancet Oncol 2001; 2: 597–607
   PubMed Web of Science ®Google Scholar
• Pui C H, Relling M V, Downing J R. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548
   PubMed Web of Science ®Google Scholar
• Ludwig W D, Haferlach T, Schoch C. Classification of acute leukemias: perspective I. New Directions for Clinical Research. Treatment of Acute Leukemias, C H Pui. Humana Press, Totowa, NJ 2003; 3–41
   Google Scholar
• Raimondi S C, Zhou Y, Mathew S, et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003; 98: 2715–2722
   PubMed Web of Science ®Google Scholar
• Talby L, Chambost H, Roubaud M-C, et al. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes. Leukemia Res 2006; 30: 665–676
   Google Scholar
• Coustan-Smith E, Ribeiro R C, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006; 108: 97–102
   PubMed Web of Science ®Google Scholar
• Lucio P, Parreira A, Van Den Neemd M W, et al. Flow cytometric analysis of normal B cell differenciation: a frame of reference for the detection of minimal residual disease in preB-ALL. Leukemia 1999; 13: 419–427
   PubMed Web of Science ®Google Scholar
• Weir E G, Cowan K, Lebau P, Borowitz M J. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13: 558–567
   PubMed Web of Science ®Google Scholar
• Campana D, Coustain Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139–152
   PubMedGoogle Scholar
• Howard S C, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004; 291: 2471–2475
   PubMed Web of Science ®Google Scholar
• Pui C H, Evans W E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178
   PubMed Web of Science ®Google Scholar